Evofem Biosciences amends 8-K; annual meeting to vote on 6x share increase to 3B, notes at 8% convertible at $1.25

Evofem Biosciences, Inc.

Annual meeting on Sep 14, 2023; proposal to amend charter to increase authorized shares from 500M to 3B.
Notes: 8% interest (12% on default), convertible at $1.25/share, maturity Aug 4, 2026.
Registration rights agreement requires S-1 filing within 90 days of closing; 2% liquidated damages for delays.
Record date for meeting set as Aug 7, 2023; auditor ratification and advisory vote on executive comp also on ballot.
Notes are senior-subordinate obligations of Evofem, not subsidiaries; beneficial ownership limitation of 4.99% (adjustable to 9.99%).

item 1.01 item 5.07

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Evofem Biosciences, Inc. entered into Securities Purchase Agreement.

Action: entry
Agreement: notes offering

Exact text from the filing

.01 Material Definitive Agreement Securities Purchase Agreement. Notes The Notes will be the senior subordinate obligations of the Company and not the financial obligations of our subsidiaries.

View on SEC.gov

Browse all material agreements →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-029433

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.